Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 5/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP4 | P49662 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18954755 | 0.85 | CASP3 (0.46) | CASP3CES1TTRCASP1CASP4 | |
| SCHEMBL17866842 | 0.82 | MAPT (0.49) | CASP3CES1TTRCASP1CASP4 | |
| SCHEMBL30704875 | 0.76 | CASP3 (0.62) | CASP3CES1TTRCASP1CASP4 | |
| SCHEMBL7780180 | 0.76 | CES1 (0.55) | CASP3CES1TTRCASP1CASP4 | |
| SCHEMBL8296661 | 0.76 | CASP3 (0.62) | CASP3CES1TTRCASP1CASP4 | |
| SCHEMBL31536334 | 0.76 | CES1 (0.55) | CASP3CES1TTRCASP1CASP4 | |
| SCHEMBL6318430 | 0.76 | CA9 (0.39) | TTRALDH1A1KMT2A | |
| SCHEMBL6318515 | 0.76 | CA9 (0.39) | TTRALDH1A1KMT2A | |
| SCHEMBL9525319 | 0.75 | ALDH1A1 (0.47) | CASP3CES1MEN1ALDH1A1KMT2A | |
| SCHEMBL6316922 | 0.73 | ALDH1A1 (0.42) | TTRMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | disclosed |
| EP-1135123-B1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH AS (DK) | 2004-12-29 | — | — | EP | disclosed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | disclosed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | disclosed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | disclosed |
| EP-0432648-B1 | Isatine derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-08-02 | — | — | EP | disclosed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| US-5192792-A | Isatine derivatives, and their method of use | WARNER-LAMBERT COMPANY (US) | 1993-03-09 | — | — | US | disclosed |
| US-5164404-A | HYDRAZONE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 1992-11-17 | — | — | US | disclosed |
| EP-0503349-A1 | Hydrazone derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1992-09-16 | — | — | EP | disclosed |
| EP-0432648-A2 | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CASP3 3446/4885CES1 2434/4885TTR 4103/4885 |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CASP3 3296/4885CES1 2526/4885TTR 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.